Clinical Trial Update: A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2a clinical trial evaluating the safety, tolerability and preliminary efficacy of topical LTX-109 for nasal carriage of MRSA/MSSA has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Methicillin-resistant Staphylococcus Aureus Nasal Carriage

Drugs mentioned

• LTX-109

Snippet

Sponsor: Lytix Biopharma AS | Conditions: Nasal Carriers MRSA | Phase 1, Phase 2 | Status: COMPLETED